to the balance between providing enough treatment to avoid recurrence, and over treating and the impact that that can have on a patient s health. and here, what s known as a non interventional clinical trial is using artificial intelligence to assess the risk of recurrence. but because this is a study where long term data is vital, the patients aren t told of the al s findings, to avoid the risk of life or death treatment decisions being based on them. french and us tech company 0wkin has partnered with the hospital to digitise over 1,500 tissue samples from women with breast cancer. this will provide some of the information needed to classify patients between having a high, intermediate or low risk of their disease returning within five years. we know that for this type of cancer, the prognosis is good, with more than 90% of patients be able to
to avoid recurrence, and over treating and the impact that that can have on a patient s health. and here, what s known as a non interventional clinical trial is using artificial intelligence to assess the risk of recurrence. but because this is a study where long term data is vital, the patients aren t told of the al s findings to avoid the risk of life or death treatment decisions being based on them. french and us tech company 0wkin has partnered with the hospital to digitise over 1,500 tissue samples from women with breast cancer. this will provide some of the information needed to classify patients between having a high, intermediate or low risk of their disease returning within five years. we know that, for this type of cancer, the prognosis is good, with more than 90% of patients be able to. to get rid of the disease.
for women worldwide. and whilst five year survival rates have massively risen thanks to better treatment and better screening there is always the fear that after you ve had treatment to get rid of it, the cancer could come back. mm. but one company is using al to try and better predict recurrence rates so that people get treatments that are more suited to them. gustave roussy, in paris, is one of the world s leading cancer centres often treating rare or complex tumours, as well as trialling some of the latest diagnostics and therapies. personalising a cancer plan can be a really tough challenge, especially when it comes to the balance between providing enough treatment to avoid recurrence and over treating and the impact that that can have on a patient s health.
gustave roussy in paris is one of the world s leading cancer centres often treating rare or complex tumours, as well as trialling some of the latest diagnostics and therapies. personalising a cancer plan can be a really tough challenge, especially when it comes to the balance between providing enough treatment to avoid recurrence and over treating and the impact that that can have on a patient s health. and here, what s known as a non interventional clinical trial is using artificial intelligence to assess the risk of recurrence. but because this is a study where long term data is vital, the patients aren t told of the al s findings to avoid the risk of life or death treatment decisions being based on them. french and us tech company owkin has partnered with the hospital to digitise over 1,500 tissue samples from women with breast cancer.
leading cancer centres, often treating rare or complex tumours, as well as trialling some of the latest diagnostics and therapies. personalising a cancer plan can be a really tough challenge, especially when it comes to the balance between providing enough treatment to avoid recurrence, and over treating and the impact that that can have on a patient s health. and here, what s known as a non interventional clinical trial is using artificial intelligence to assess the risk of recurrence. but because this is a study where long term data is vital, the patients aren t told of the al s findings to avoid the risk of life or death treatment decisions being based on them. french and us tech company owkin has partnered with the hospital to digitise over 1,500 tissue samples from women with breast cancer. this will provide some of the information needed to classify patients between having a high, intermediate or low risk of their disease